Despite concerns about the economic climate in Europe and whether or not the U.S. is headed into another recession, biotech companies around the world managed to raise $23.4 billion in 2011, up from $19.3 billion in 2010 and almost back on par with the $24.8 billion raised in the glory days of 2007. Read More
Last month, Reata Pharmaceuticals Inc. snagged $400 million from Abbott for half of its second-generation antioxidant inflammation modulator (AIM) portfolio, bucking a trend over the last few years of putting the risk on the innovator through milestone payments. (See BioWorld Today, Dec. 13, 2011.) Read More
The most obvious way to use stem cells is to differentiate them in a petri dish and transplant the resulting cells into tissues or organs that are damaged or diseased. Read More
